Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Liabilities and Shareholders Equity: 2017-2024

Historic Liabilities and Shareholders Equity for Cidara Therapeutics (CDTX) over the last 8 years, with Dec 2024 value amounting to $214.8 million.

  • Cidara Therapeutics' Liabilities and Shareholders Equity rose 219.50% to $518.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 billion, marking a year-over-year increase of 220.46%. This contributed to the annual value of $214.8 million for FY2024, which is 220.45% up from last year.
  • According to the latest figures from FY2024, Cidara Therapeutics' Liabilities and Shareholders Equity is $214.8 million, which was up 220.45% from $67.0 million recorded in FY2023.
  • Cidara Therapeutics' Liabilities and Shareholders Equity's 5-year high stood at $214.8 million during FY2024, with a 5-year trough of $47.5 million in FY2022.
  • Moreover, its 3-year median value for Liabilities and Shareholders Equity was $67.0 million (2023), whereas its average is $109.8 million.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first slumped by 36.96% in 2022, then soared by 220.45% in 2024.
  • Cidara Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $60.4 million in 2020, then rose by 24.66% to $75.3 million in 2021, then tumbled by 36.96% to $47.5 million in 2022, then soared by 41.15% to $67.0 million in 2023, then soared by 220.45% to $214.8 million in 2024.